Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is a global medical technology company focused on surgical solutions for spinal, orthopedic, and wound care disorders, with a portfolio centered on orthobiologics and spinal implant systems. The XTNT news feed on Stock Titan aggregates company-issued updates and regulatory disclosures so readers can follow how Xtant communicates its strategy, product launches, and financial performance.
Recent news releases describe Xtant’s emphasis on its core biologics business and regenerative medicine capabilities. The company has announced the commercial launch of products such as CollagenX™, a bovine collagen particulate product for surgical wound closure, and OsteoFactor Pro™, a growth factor-based biologic designed to improve bone healing across orthopedic and spine procedures. Xtant has also introduced Trivium™, a next-generation demineralized bone matrix allograft, and nanOss Strata™, a synthetic bone graft manufactured from hydroxycarbonapatite and designed to mimic human bone structure and support osteoconductivity and cellular activity.
Company news also covers strategic transactions and portfolio changes. Xtant has reported entering into, and subsequently completing, the sale of certain non-core Coflex and CoFix spinal implant assets and its Paradigm Spine GmbH international hardware business to Companion Spine entities, describing these divestitures as a way to sharpen its focus on biologics and strengthen its balance sheet.
Investors and analysts following XTNT news will find quarterly earnings announcements, including revenue trends, gross margin, net income, adjusted EBITDA, and cash flow metrics, as well as financial guidance for the year. The company also issues notices about participation in investor conferences, annual meeting details, and governance developments such as changes to its Board of Directors and amendments to equity incentive plans.
By reviewing the XTNT news stream, readers can see how Xtant presents its mission of honoring the gift of donation, its product development priorities in orthobiologics and wound closure, and the financial and strategic milestones it reports through press releases and SEC-related communications.
Summary not available.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that CEO Sean Browne will present at the H.C. Wainwright 23rd Annual Global Investment Conference, scheduled for September 13-15, 2021. A pre-recorded presentation will be available on the company's website starting September 13, 2021, at 7:00 AM Eastern Time and will remain accessible for 90 days. Xtant Medical focuses on developing and commercializing spinal implant systems and orthobiologics for spinal fusion.
Xtant Medical Holdings, focused on surgical solutions for spinal disorders, reported a 42% revenue increase to $15.0 million for Q2 2021 compared to the previous year. The gross margin improved to 63.5% from 62.2%. The net loss shrank to $0.7 million or $0.01 per share, significantly better than the $2.5 million loss in Q2 2020. The company closed a $20 million debt refinancing and reported a Non-GAAP Adjusted EBITDA of $0.9 million. Xtant's expansion in sales force and distribution aims to enhance future growth.
Xtant Medical Holdings, Inc. (XTNT) will release its financial results for Q2 2021 on August 5, 2021, before the market opens. The conference call will be hosted by CEO Sean Browne and CFO Greg Jensen at 9:00 AM ET, providing insights into the company’s performance in the spinal disorder market. Investors can access the call via dial-in or webcast, with a replay available on their website.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will have its CEO Sean Browne present at the Canaccord Musculoskeletal Conference on May 20, 2021, at 3:00 PM ET. The presentation focuses on innovations in spinal surgery solutions. Investors can access a live webcast on the company's website. A replay will be available for 90 days post-event. Xtant Medical specializes in spinal implant systems, offering comprehensive orthobiologics for complex spine procedures.
Xtant Medical Holdings, Inc. (XTNT) reported Q1 2021 results, with revenue of $12.5 million, a decrease from $14.8 million in Q1 2020, mainly due to COVID-19 impacts. Operating expenses fell to $8.1 million from $11.0 million as a result of lower sales and wages. The company incurred a net loss of $29,000, a significant improvement from $2.5 million in the prior period. Non-GAAP Adjusted EBITDA rose to $0.8 million from $0.3 million. Xtant raised $18.4 million from a private placement and secured $20 million in debt refinancing to bolster growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has filed a universal shelf registration statement on Form S-3 with the SEC, allowing the company to offer and sell various securities up to $150 million over three years. This filing is aimed at enhancing capital market access for financing growth initiatives. Additionally, it permits OrbiMed Advisors, LLC to sell up to 18,218,374 shares of XTNT common stock. The company currently has no specific plans for issuing securities under this registration, and proceeds from any stock sales will not benefit Xtant directly.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) has entered into new credit agreements with MidCap Financial Trust, which include a $12 million secured term loan at 7% interest and an $8 million secured revolving credit facility at 4.5% interest. These agreements replace the existing loan from OrbiMed, fully repaying that debt. The new financing is aimed at enhancing the company's balance sheet and supporting strategic growth initiatives.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) will release its Q1 2021 financial results on May 11, 2021, before market open. A conference call, led by CEO Sean Browne and CFO Greg Jensen, will take place at 9:00 AM ET on the same day to discuss the results. Interested parties can join the call using the provided dial-in numbers or register for the webcast. The company specializes in surgical solutions for spinal disorders, including orthobiologics and spinal implant systems.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced that it is not aware of any undisclosed corporate developments accounting for the recent surge in its share price and trading volume. The company focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implant systems. Their commitment to integrity and customer service remains a priority as they navigate the market fluctuations.